Showing 7991-8000 of 8172 results for "".
- Ulthera Announces Indication for Decolletage in Asiahttps://practicaldermatology.com/news/20120709-ulthera_announces_indication_for_dcolletage_in_asia/2459776/Ulthera, Inc., a global, growth-stage medical device company, announced the commercial availability of the Ulthera System in select Asian countries to non-invasively treat the skin on the chest area, or décolletage. The Ulthera Sys
- CellCeuticals Nominated for Cosmetic Innovation Awardhttps://practicaldermatology.com/news/20120629-cellceuticals_nominated_for_cosmetic_innovation_award/2459777/CellCeuticals Skin Care, Inc., Biomedical Skin Treatments was named a finalist in two categories by the Independent Cosmetic Manufacturers and Distributors Association (ICMAD). InterActive Moisture Serum 2 was nominated for Best Skin Care P
- Provectus Pharmaceuticals Presents Phase II Data on PV-10https://practicaldermatology.com/news/20120627-provectus_pharmaceuticals_presents_phase_ii_data_on_pv-10/2459780/Provectus Pharmaceuticals, Inc. (OTCBB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, presented its top-line final data from the Phase II clinical trial of PV-10 for metastatic melanoma. Results were showcased at the
- National Eczema Blog Launcheshttps://practicaldermatology.com/news/20120626-national_eczema_blog_launches/2459781/The National Eczema Association recently created a blog featuring guest bloggers on a variety of eczema-related topics. The first post, written by the blogger named “Spanish Key,” provides a patient perspective on eczema research topics and h
- Data Support Vismodegib for Metastatic, Locally Advanced BCChttps://practicaldermatology.com/news/20120613-data_support_vismodegib_for_metastatic_locally-advanced_bcc/2459783/New data demonstrate the anti-tumor activity of vismodegib (Erivedge, Genentech) 150mg daily in metastatic and locally advanced basal cell carcinoma (BCC). (N Engl J Med; 366:2171-2179) The study found that the independently assessed response rate was 30 percent in patients with metastatic BCC (n=33
- EWG Releases 2012 Sunscreen Guide and Apphttps://practicaldermatology.com/news/20120608-ewg_releases_2012_sunscreen_guide_and_app/2459787/After rating 257 brands and more than 1,800 products, the Environmental Working Group (EWG) released its sixth annual Guide to Summer Sun. EWG recommends 1 in 4 of more than 800 beach and sport sunscreens, compared to 1 in 5 l
- Suneva to Acquire Worldwide Rights to Refissa(R)https://practicaldermatology.com/news/20120604-suneva_to_acquire_worldwide_rights_to_refissar/2459789/Suneva Medical , a privately-held aesthetics company, will acquire worldwide rights to Refissa® and its marketed generic equivalent from Spear Pharmaceuticals. The portfolio contains the only tretinoin creams with
- New Isotretinoin Formulation Approvedhttps://practicaldermatology.com/news/20120529-new_isotretinoin_formulation_approved/2459794/A novel isotretinoin formulation for the treatment of severe recalcitrant nodular acne will soon be available from Ranbaxy. FDA approved Absorica (cis-isotretinoin), which
- Dermatologists Can Spot Early Psoriatic Arthritishttps://practicaldermatology.com/news/20120521-dermatologists_can_spot_early_psoriatic_arthritis/2459795/Clinical dermatologists could help diagnose early psoriatic arthritis (EPsA) through the use of patient questioning and subsequent imaging studies in collaboration with rheumatologists and radiologists, data suggest. (
- Merz Realignment Focuses on Synergieshttps://practicaldermatology.com/news/20120518-merz_realignment_focuses_on_synergies/2459796/Merz is realigning and integrating its core businesses in the United States and Canada into one organization, with a single leadership team, the company announced. According to Merz, "the newly aligned structure is designed to stre